Tu1727 – Rapidity of Symptomatic and Inflammatory Biomarker Improvements Following Upadacitinib Induction Treatment: Data from the U-Achieve Study

Geert D’Haens(Amsterdam University Medical Centers), Séverine Vermeire(KU Leuven), Julián Panés(Hospital Clínic de Barcelona), Fabio Cataldi(Pfizer (United States)), Edward V. Loftus(Mayo Clinic), Peter Higgins(Michigan Medicine), Bidan Huang(AbbVie (United States)), Wen Zhou, Remo Panaccione(University of Calgary), Wangang Xie(AbbVie (United States)), Wan‐Ju Lee
Gastroenterology
May 1, 2019
10.1016/s0016-5085(19)39713-6
Cited by 1

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k